...
首页> 外文期刊>Nature Communications >Bioengineering of injectable encapsulated aggregates of pluripotent stem cells for therapy of myocardial infarction
【24h】

Bioengineering of injectable encapsulated aggregates of pluripotent stem cells for therapy of myocardial infarction

机译:多能干细胞可注射包封的聚集体的生物工程用于心肌梗死的治疗

获取原文
           

摘要

It is difficult to achieve minimally invasive injectable cell delivery while maintaining high cell retention and animal survival for in vivo stem cell therapy of myocardial infarction. Here we show that pluripotent stem cell aggregates pre-differentiated into the early cardiac lineage and encapsulated in a biocompatible and biodegradable micromatrix, are suitable for injectable delivery. This method significantly improves the survival of the injected cells by more than six-fold compared with the conventional practice of injecting single cells, and effectively prevents teratoma formation. Moreover, this method significantly enhances cardiac function and survival of animals after myocardial infarction, as a result of a localized immunosuppression effect of the micromatrix and the in situ cardiac regeneration by the injected cells.
机译:对于心肌梗塞的体内干细胞治疗,难以在维持高细胞保留率和动物存活率的同时实现微创可注射细胞递送。在这里,我们显示了预分化成早期心脏谱系并封装在生物相容性和可生物降解的微基质中的多能干细胞聚集体,适合于注射给药。与注射单细胞的常规方法相比,该方法将注射细胞的存活率显着提高了六倍以上,并有效地防止了畸胎瘤的形成。此外,由于微基质的局部免疫抑制作用和所注射细胞的原位心脏再生,该方法显着增强了心肌梗塞后动物的心脏功能和存活率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号